scholarly journals Epidemiology, molecular epidemiology, and risk factors for renal cell carcinoma

2011 ◽  
pp. 120-127
Author(s):  
Chiara Paglino ◽  
Ilaria Imarisio ◽  
Bruno Rovereto
Keyword(s):  
Risk Factors ◽  
Renal Cell Carcinoma ◽  
Molecular Epidemiology ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Antihypertensive Drugs ◽  
Kidney Diseases ◽  
Cell Cancer ◽  
Chlorinated Solvents ◽  
Kidney Tumors

Despite only accounting for approximately 2% of all new primary cancer cases, renal cell carcinoma (RCC) incidence has dramatically increased over time. Incidence rates vary greatly according to geographic areas, so that it is extremely likely that exogenous risk factors could play an important role in the development of this cancer. Several risk factors have been linked with RCC, including cigarette smoking, obesity, hypertension (and antihypertensive drugs), chronic kidney diseases (also dialysis and transplantation), as well as the use of certain analgesics. Furthermore, although RCC has not generally been considered an occupational cancer, several types of occupationally-derived exposures have been implicated in its pathogenesis. These include exposure to asbestos, chlorinated solvents, gasoline, diesel exhaust fumes, polycyclic aromatic hydrocarbons, printing inks and dyes, cadmium and lead. Finally, families with a predisposition to the development of renal neoplasms were identified and the genes involved discovered and characterized. Therefore, there are now four well-characterized, genetically determined syndromes associated with an increased incidence of kidney tumors, i.e., Von Hippel Lindau (VHL), Hereditary Papillary Renal Carcinoma (HPRC), Birt-Hogg-Dubé Syndrome (BHD), and Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC). This review will address present knowledge about the epidemiology, molecular epidemiology and risk factors of RCC.

Epidemiology, molecular epidemiology, and risk factors for renal cell carcinoma

2007 ◽  
Vol 1 (2) ◽  
pp. 120-127 ◽  
Author(s):  
Chiara Paglino ◽  
Ilaria Imarisio ◽  
Bruno Rovereto
Keyword(s):  
Risk Factors ◽  
Renal Cell Carcinoma ◽  
Molecular Epidemiology ◽  
Cell Carcinoma ◽  
Renal Cell

scholarly journals Epidemiology, molecular epidemiology, and risk factors for renal cell carcinoma

10.4081/146 ◽  
2011 ◽  
Vol 1 (2) ◽  
Author(s):  
Chiara Paglino ◽  
Ilaria Imarisio ◽  
Bruno Rovereto
Keyword(s):  
Risk Factors ◽  
Renal Cell Carcinoma ◽  
Molecular Epidemiology ◽  
Cell Carcinoma ◽  
Renal Cell

scholarly journals Risk Factors for Renal Cell Cancer in a Japanese Population

2009 ◽  
Vol 3 ◽  
pp. CMO.S2669 ◽  
Author(s):  
Masakazu Washio ◽  
Mitsuru Mori
Keyword(s):  
Risk Factors ◽  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Dietary Habits ◽  
Large Population ◽  
Cell Cancer ◽  
Black Tea ◽  
Increased Risk

The incidence of renal cell cancer has been increasing worldwide. Although the incidence of renal cell cancer in Japan is lower than the rates in the other industrialized countries, there is no doubt that it is increasing. In this paper, we would like to introduce the result of our studies, which evaluate the risk factors for renal cell cancer in Japan. Hypertension, diabetes mellitus, kidney diseases, fondness for fatty food and black tea showed an increased risk of renal cell carcinoma while an intake of starchy roots such as taro, sweet potato and potato reduced the risk of renal cell carcinoma. In Japan, however, drinking black tea may be a surrogate for westernized dietary habits while eating starchy roots may be a surrogate for traditional Japanese dietary habits. Further studies may be needed to evaluate risk factors for renal cell cancer because the number of renal cancer cases was small in our studies in spite of a large population-based cohort study.

scholarly journals Adverse drug reactions associated with sunitinib therapy: Characteristics and risk factors

2020 ◽  
pp. 145-145
Author(s):  
Snezana Mugosa ◽  
Zoran Dzamic ◽  
Majda Sahman-Zaimovic ◽  
Nevenka Lukovac-Janjic
Keyword(s):  
Risk Factors ◽  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Adverse Drug Reactions ◽  
Renal Cell ◽  
Subcutaneous Tissue ◽  
Significant Risk ◽  
Drug Reactions ◽  
Kidney Tumors ◽  
Clinical Center

Background/Aim: Kidney tumors account for 2-3% of all tumors. Renal cell carcinoma is the tenth most common malignancy. Sunitinib ise used as the first treatment line in patients with a good and intermediate prognosis. The main goal of this study is to analyze the risk factors, frequency and adverse drug reactions (ADRs) of sunitinib in patients with metastatic renal cell carcinoma. Methods: The retropective study included 170 patients treated in Clinic for Oncology of the Clinical Center of Montenegro, Urology Clinic of the Clinical Center of Serbia and Clinic for Oncology of the Clinical Center Nis. As a data source, we used patient medical histories and/or electronic patient records. ADRs were characterized by using Rawlins and Thompson classification. Each ADRs severity was assessed in accordance with the WHO criteria. Causality was assessed using the Naranjo probability scale. Results: Adverse drug reactions of sunitinib occurred in 152 patients (89,4%). ADRs were 89% type A and 11% type C. Disorders of the blood and lymphatic system, gastrointestinal disorders and disorders of the skin and subcutaneous tissue were the most common manifestations of ADRs of sunitinib. Causality assesment was most commonly classified as certain (60%). Serious ADRs occurred in 4.5% of patients. Most patients recovered without consequences. The most common manifestations of ADRs were: leukopenia, hypothyroidism, thrombocytopenia, diarrhea, stomatitis, asthenia and hypertension. All ADRs were expected. The number of concomitant medications and the duration of therapy were shown to be the most significant risk factors for adverse reactions to sunitinib. Conclusion: Our study shows that the incidence of ADRs of sunitinib in patients with kidney cancer is high. The ADRs were mostly moderate and mild in intensity and occurred as a consequence of the pharmacological action of the drug. It is necessary to conduct continuous education of medical oncologists in the field of the safe use of drugs monitoring, as well as patients on sunitinib therapy, in order to improve their awareness of the ADRs of sunitinib and the risk factors that lead to them, with the aim of reducing their frequency.

scholarly journals Epidemiology, molecular epidemiology, and risk factors for renal cell carcinoma

2011 ◽  
Vol 1 (2) ◽  
pp. 120
Author(s):  
Chiara Paglino ◽  
Ilaria Imarisio ◽  
Bruno Rovereto
Keyword(s):  
Risk Factors ◽  
Renal Cell Carcinoma ◽  
Molecular Epidemiology ◽  
Cell Carcinoma ◽  
Renal Cell

scholarly journals A convention-radiomics CT nomogram for differentiating fat-poor angiomyolipoma from clear cell renal cell carcinoma

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Yanqing Ma ◽  
Weijun Ma ◽  
Xiren Xu ◽  
Zheng Guan ◽  
Peipei Pang
Keyword(s):  
Risk Factors ◽  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Logistic Model ◽  
Clear Cell ◽  
Cell Renal Cell Carcinoma ◽  
Entire Cohort ◽  
Conventional Ct ◽  
Radiomics Signature

AbstractThis study aimed to construct convention-radiomics CT nomogram containing conventional CT characteristics and radiomics signature for distinguishing fat-poor angiomyolipoma (fp-AML) from clear-cell renal cell carcinoma (ccRCC). 29 fp-AML and 110 ccRCC patients were enrolled and underwent CT examinations in this study. The radiomics-only logistic model was constructed with selected radiomics features by the analysis of variance (ANOVA)/Mann–Whitney (MW), correlation analysis, and Least Absolute Shrinkage and Selection Operator (LASSO), and the radiomics score (rad-score) was computed. The convention-radiomics logistic model based on independent conventional CT risk factors and rad-score was constructed for differentiating. Then the relevant nomogram was developed. Receiver operation characteristic (ROC) curves were calculated to quantify the accuracy for distinguishing. The rad-score of ccRCC was smaller than that of fp-AML. The convention-radioimics logistic model was constructed containing variables of enhancement pattern, VUP, and rad-score. To the entire cohort, the area under the curve (AUC) of convention-radiomics model (0.968 [95% CI 0.923–0.990]) was higher than that of radiomics-only model (0.958 [95% CI 0.910–0.985]). Our study indicated that convention-radiomics CT nomogram including conventional CT risk factors and radiomics signature exhibited better performance in distinguishing fp-AML from ccRCC.

Risk Factors for Ipsilateral Adrenal Involvement in Renal Cell Carcinoma

Urology ◽  
2008 ◽  
Vol 72 (2) ◽  
pp. 354-358 ◽  
Author(s):  
Keiichi Ito ◽  
Hayakazu Nakazawa ◽  
Ken Marumo ◽  
Seiichiro Ozono ◽  
Tatsuo Igarashi ◽  
...  
Keyword(s):  
Risk Factors ◽  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell

scholarly journals Metastatic renal cell carcinoma of unknown primary site. Clinical follow-up

2020 ◽  
Vol 22 (3) ◽  
pp. 149-153
Author(s):  
N. A. Ognerubov ◽  
T. S. Antipova ◽  
G. E. Gumareva
Keyword(s):  
Computed Tomography ◽  
Renal Cell Carcinoma ◽  
Adrenal Gland ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Cell Cancer ◽  
Primary Site ◽  
The Right

Renal cell cancer metastases without evidence of a primary tumor are extremely rare. These variants are usually showed as a spontaneous description of single clinical cases. Aim.This contribution is a clinical follow-up of synchronous renal cell cancer metastases of unknown primary site. Results.A 52-year-old patient U. with a history of increased blood pressure, up to 170/100 mmHg for the last 5 years, who had undergone many instrumental examinations, including ultrasound examination, because of this disease. The computed tomography of the abdomen showed a 4975 mm heterogeneous tumor in the right adrenal gland in October 2017. The combined positron emission and X-ray computed tomography showed a 795441 mm mass in the right adrenal gland, associated with elevated fluorodeoxyglucose metabolic activity SUVmax 7.25. Focal accumulation of the radiopharmaceutical SUVmax 4.31 in a 171124 mm mass was detected in the space of bifurcation in the mediastinum. The lytic lesion (1015 mm) was found in right superior L3 articular process. The patient underwent retroperitoneoscopic adrenalectomy and thoracoscopic removal of mediastinal tumor in November 2017 because of the oligometastatic nature of the process. The histological study identified clear-cell carcinoma with areas of papillary structure in the right adrenal gland. The immunohistochemical study showed carcinoma cells intensively expressing CD10, and some other cells RCC. The immune phenotype of the tumor was identified as clear-cell renal cell carcinoma. The immunohistological and immunohistochemical analysis reviled the metastases of the same variant of renal cell carcinoma in one of 9 lymph nodes. The patient was treated with pazopanib. The primary renal tumor was not detected during the dynamic observation, including the application of annual combined positron emission and X-ray computed tomography. The patient is alive without disease progression with a follow-up of 32 months. Conclusion.Metastases of clear-cell renal cell carcinoma, including adrenal gland, without evidence of a primary site are extremely rare. The main method of treatment is a combination of surgery and targeted therapy, providing long-term local control of the course of the disease.

scholarly journals Advanced and metastatic renal cell carcinoma – Ain Shams Clinical Oncology Department Experience

2020 ◽  
Vol 10 (1) ◽  
pp. 18
Author(s):  
Ahmed Nagy ◽  
Mona Kamal ◽  
Hesham El Halawani
Keyword(s):  
Risk Factors ◽  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Clinical Oncology ◽  
Renal Cell ◽  
Older Patients ◽  
Treatment Options ◽  
Tumor Grade ◽  
Kaplan Meier ◽  
Younger Age

Background: Renal cell carcinoma is a rare tumor and till recently few treatment options were available. It is poorly understood why people develop RCC since only a few etiologic factors have been clinically identified as risk factors for RCC.Purpose: To analyze our experience at Ain Shams University Clinical Oncology department in Egypt with patients presenting with advanced renal cell carcinoma to provide a correlations between clinic-pathological factors, treatment and survival outcomes.Methodology: Retrospective review of the data of 54 patients who were diagnosed as RCC and presented to Ain Shams University Clinical Oncology department in Egypt from 1 May 2013 till 1 May 2015. Descriptive and clinic-pathological data were described using simple and relative frequencies. Survival outcome for the patients will be described using Kaplan Meier curves stratified according to morphology, age group and treatment received.Results: The sample included 54 patients (53.7% were males) of whom 14.3% were less than 40 years and 3.7% were elderly (≥ 70 years old). The median age was 55.5 years (SD ± 13.6 , range 19-71). Median PFS was 6.5 months (SD ± 12.3846 Range 43) while the median OS was 13 months (SD ± 12.161 Range 46). PFS in patients aged below 55.5 years was 9 months (95% CI=6.509-11.491) compared to 4 months (95% CI=2.704-5.296) in older patients (p = .004). PFS in patients who achieved PR after sunitinb was 17 months (95% CI=6.916-27.084) compared to 5 months (95% CI=3.699-6.301) in patients who didn’t achieved PR (p < .001). OS in patients aged below 55.5 years was 15 months (95% CI=9.131-20.869) compared to 11 months (95% CI=8.947-13.053) in older patients (p = .012). Favorable pathology status was associated with prolonged OS of 14 months (95% CI= 9.403-18.597) versus 11 months (95% CI=8.363-13.637) for unfavourable pathology status (p = .11). Low grades histopathogy was associated with prolonged OS of 44 months (95% CI= 38.456-49.544) versus 12 months (95% CI=10.077-13.923) for higher grades (p = < .001).Conclusion: Multivariate analyses supported a conclusion that younger age was an independent prognostic factor for survival along with other known risk factors such as tumor grade and pathology status.

Sign in / Sign up

Export Citation Format

Share Document